Focus on 16p13.3 Locus in Colon Cancer.

PLoS One 2015 29;10(7):e0131421. Epub 2015 Jul 29.

Department of Gastroenterology-Digestive Oncology, Ghent University Hospital, Ghent, Belgium.

Background: With one million new cases of colorectal cancer (CRC) diagnosed annually in the world, CRC is the third most commonly diagnosed cancer in the Western world. Patients with stage I-III CRC can be cured with surgery but are at risk for recurrence. Colorectal cancer is characterized by the presence of chromosomal deletions and gains. Large genomic profiling studies have however not been conducted in this disease. The number of a specific genetic aberration in a tumour sample could correlate with recurrence-free survival or overall survival, possibly leading to its use as biomarker for therapeutic decisions. At this point there are not sufficient markers for prediction of disease recurrence in colorectal cancer, which can be used in the clinic to discriminate between stage II patients who will benefit from adjuvant chemotherapy. For instance, the benefit of adjuvant chemotherapy has been most clearly demonstrated in stage III disease with an approximately 30 percent relative reduction in the risk of disease recurrence. The benefits of adjuvant chemotherapy in stage II disease are less certain, the risk for relapse is much smaller in the overall group and the specific patients at risk are hard to identify.

Materials And Methods: In this study, array-comparative genomic hybridization analysis (array-CGH) was applied to study high-resolution DNA copy number alterations in 93 colon carcinoma samples. These genomic data were combined with parameters like KRAS mutation status, microsatellite status and clinicopathological characteristics.

Results: Both large and small chromosomal losses and gains were identified in our sample cohort. Recurrent gains were found for chromosome 1q, 7, 8q, 13 and 20 and losses were mostly found for 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22. Data analysis demonstrated that loss of chromosome 4 is linked to a worse prognosis in our patients series. Besides these alterations, two interesting small regions of overlap were identified, which could be associated with disease recurrence. Gain of the 16p13.3 locus (including the RNA binding protein, fox-1 homolog gene, RBFOX1) was linked with a worse recurrence-free survival in our patient cohort. On the other hand, loss of RBFOX1 was only found in patients without disease recurrence. Most interestingly, above mentioned characteristics were also found in stage II patients, for whom there is a high medical need for the identification of new prognostic biomarkers.

Conclusions: In conclusion, copy number variation of the 16p13.3 locus seems to be an important parameter for prediction of disease recurrence in colon cancer.

Download full-text PDF

April 2016
26 Reads

Publication Analysis

Top Keywords

disease recurrence
colorectal cancer
16p133 locus
adjuvant chemotherapy
linked worse
recurrence-free survival
prediction disease
benefit adjuvant
copy number
colon cancer
stage patients
recurrence colorectal
homolog gene
risk hard
specific patients


(Supplied by CrossRef)
Adjuvant Chemotherapy for Stage II Colon Cancer: Everyone Still Needs a Tailor
MF McGee et al.
Annals of Surgical Oncology 2014
Current issues in adjuvant treatment of stage II colon cancer
T Andre et al.
Annals of Surgical Oncology 2006
Localized Colon Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines
AB Benson et al.
Journal of the National Comprehensive Cancer Network 2013
Genetic Changes and Histopathological Types in Colorectal Tumors from Patients with Familial Adenomatous Polyposis
M Miyaki et al.
Cancer Research 1990
Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer
VJ Bubb et al.
Oncogene 1996
Expression of the nuclear oncogene p53 in colon tumours
FM van den Berg et al.
Journal of Pathology 1989

Similar Publications